#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acquired C1 inhibitor deficiency Acute lymphocytic leukaemia recurrent Piriformis syndrome T-cell lymphoma Ureteric cancer Oesophageal adenocarcinoma stage III Cytokine release syndrome Essential thrombocythaemia Meningococcal immunisation Angiosarcoma non-metastatic Marginal zone lymphoma recurrent Polyneuropathy Follicle centre lymphoma follicular grade I, II – III Pseudomyxoma peritonei Heavy menstrual bleeding More trials…

    Learn about Rare Diseases

    Ornithine transcarbamoylase deficiency – Basic Information Sarcoidosis – Basic Information Langerhans’ cell histiocytosis Waldenstrom’s macroglobulinaemia – Life with Disease Familial amyotrophic lateral sclerosis – Basic Information Haemophilia B without inhibitors – Trials in Disease Metachromatic leukodystrophy – Diagnostics Mast cell activation syndrome – Diagnostics Waldenstrom’s macroglobulinaemia – Diagnostics Pulmonary fibrosis – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    GRNA1599 99MTC-EUK-(SO3)CY5-MAS3 Cariprazine Hydrochloride Talazoparib Perflubutane Fluvastatin Auto4 Rbl005.3 Diclofenac Diethylamine Hydrocortisone Ph. Eur. Olive Oil, Refined Placebo Albiglutide Mecasermin Rinfabate Tilsotolimod Sodium Umeclidinium Bromide YL201 Grwd5769 Setrusumab Clenbuterol Hydrochloride More therapies…

    Learn about Your Condition

    Partial lipodystrophy Thyroid disorder Oral lichen planus Myotonia Migraine with aura Colon cancer metastatic Pancreatitis relapsing Craniopharyngioma Haematological malignancy Restless legs syndrome Infection Neonatal respiratory failure Alpha-1 antitrypsin deficiency Neuroblastoma recurrent Multifocal motor neuropathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Jules Bordet

Institut Jules Bordet

Mogfcvvgvnuoiumve 9vy Avoigladxkk 1lcwi Btphtvx

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine
    Austria Belgium Denmark Finland France Germany +6

  • Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Italy +5

  • Study of RMC-6291 with ivonescimab drug combination in patients with advanced RAS‑mutated solid tumors

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Cetuximab
    • Ivonescimab
    Belgium France Germany Greece Ireland Italy +3

  • Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil
    • Trifluridine
    Belgium Germany Greece Portugal Spain

  • Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Durvalumab
    Austria Belgium Bulgaria France Germany Greece +8

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • LY4170156
    • Bevacizumab
    • Carboplatin
    Austria Belgium Czechia Denmark France Germany +9

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Trastuzumab
    Austria Belgium Czechia France Germany Hungary +5

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Sacituzumab Tirumotecan
    Austria Belgium Czechia Denmark Finland France +9

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • INCB123667
    • Topotecan Hydrochloride
    • Doxorubicin Hydrochloride
    Belgium France Germany Ireland Italy The Netherlands +2

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    3 1 1
    Investigated Drugs:
    • Goserelin Acetate
    • Pertuzumab
    • Trastuzumab
    Belgium Finland France Germany Italy Poland +1
1 2 3 … 22
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!